X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs ALKEM LABORATORIES - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH ALKEM LABORATORIES PANACEA BIOTECH/
ALKEM LABORATORIES
 
P/E (TTM) x -21.1 - - View Chart
P/BV x 2.5 7.1 35.2% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 PANACEA BIOTECH   ALKEM LABORATORIES
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
ALKEM LABORATORIES
Mar-16
PANACEA BIOTECH/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1491,589 9.4%   
Low Rs821,232 6.7%   
Sales per share (Unadj.) Rs84.1417.5 20.2%  
Earnings per share (Unadj.) Rs-18.356.3 -32.5%  
Cash flow per share (Unadj.) Rs-6.764.7 -10.4%  
Dividends per share (Unadj.) Rs012.70 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs83.7292.9 28.6%  
Shares outstanding (eoy) m61.25119.57 51.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.43.4 40.6%   
Avg P/E ratio x-6.325.1 -25.2%  
P/CF ratio (eoy) x-17.221.8 -79.1%  
Price / Book Value ratio x1.44.8 28.7%  
Dividend payout %022.6 0.0%   
Avg Mkt Cap Rs m7,074168,653 4.2%   
No. of employees `0002.8NA-   
Total wages/salary Rs m1,4499,171 15.8%   
Avg. sales/employee Rs Th1,874.1NM-  
Avg. wages/employee Rs Th527.0NM-  
Avg. net profit/employee Rs Th-407.7NM-  
INCOME DATA
Net Sales Rs m5,15449,915 10.3%  
Other income Rs m1001,645 6.1%   
Total revenues Rs m5,25451,561 10.2%   
Gross profit Rs m-7668,482 -9.0%  
Depreciation Rs m7111,006 70.7%   
Interest Rs m1,503671 224.1%   
Profit before tax Rs m-2,8818,451 -34.1%   
Minority Interest Rs m11-114 -9.5%   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m171,606 1.0%   
Profit after tax Rs m-1,1216,731 -16.7%  
Gross profit margin %-14.917.0 -87.5%  
Effective tax rate %-0.619.0 -3.1%   
Net profit margin %-21.813.5 -161.3%  
BALANCE SHEET DATA
Current assets Rs m3,81027,062 14.1%   
Current liabilities Rs m8,36515,324 54.6%   
Net working cap to sales %-88.423.5 -375.9%  
Current ratio x0.51.8 25.8%  
Inventory Days Days15667 234.1%  
Debtors Days Days6741 162.9%  
Net fixed assets Rs m14,48012,610 114.8%   
Share capital Rs m61239 25.6%   
"Free" reserves Rs m90334,490 2.6%   
Net worth Rs m5,12735,027 14.6%   
Long term debt Rs m5,8321,212 481.3%   
Total assets Rs m19,43354,387 35.7%  
Interest coverage x-0.913.6 -6.7%   
Debt to equity ratio x1.10 3,288.2%  
Sales to assets ratio x0.30.9 28.9%   
Return on assets %2.013.6 14.4%  
Return on equity %-21.919.2 -113.8%  
Return on capital %3.624.9 14.6%  
Exports to sales %24.512.9 189.4%   
Imports to sales %10.23.1 330.0%   
Exports (fob) Rs m1,2646,461 19.6%   
Imports (cif) Rs m5251,540 34.1%   
Fx inflow Rs m1,5396,563 23.5%   
Fx outflow Rs m9423,012 31.3%   
Net fx Rs m5973,552 16.8%   
CASH FLOW
From Operations Rs m5997,259 8.3%  
From Investments Rs m-4381,864 -23.5%  
From Financial Activity Rs m-303-9,273 3.3%  
Net Cashflow Rs m-141-150 94.2%  

Share Holding

Indian Promoters % 74.5 66.9 111.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 33.1 1.8%  
FIIs % 1.3 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 0.0 -  
Shareholders   10,259 68,381 15.0%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   AUROBINDO PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  MERCK LTD  

Compare PANACEA BIOTECH With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Stock Market's Sudden Crash; Rising Oil Prices; Banking Stocks and Top Cues in Action Today(Pre-Open)

The Indian share markets ended lower on Friday. The S&P BSE Sensex partially recovered after crashing 1,000 points in intraday trade to settle 280 points lower.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Sep 21, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS